UBS Sees $15 Billion Sales Potential for Eli Lilly’s (LLY) Obesity Treatment Orforglipron

Group 1 - Eli Lilly & Company is recognized as one of the most active stocks to buy, with a Buy rating and a price target of $895 from UBS following positive Phase 3 trial results for its obesity treatment [1][2] - The ATTAIN-2 trial results for orforglipron show efficacy comparable to Novo Nordisk's Wegovy, indicating a more optimistic commercial outlook than previously anticipated [2] - UBS maintains a peak sales forecast of $15 billion for orforglipron, pending full data presentation at the European Association for the Study of Diabetes (EASD) [3] Group 2 - Eli Lilly & Company is a major global pharmaceutical company, established in 1876, that develops, manufactures, and distributes a wide range of drugs [3]